Belatacept: a novel biologic for maintenance immunosuppression after renal transplantation (Q37859368)

24 August 2017

1 reference

title

Belatacept: a novel biologic for maintenance immunosuppression after renal transplantation (English)

1 reference

24 August 2017

1 reference

3

1 reference

24 August 2017

Spencer T Martin

1

1 reference

24 August 2017

Eric M Tichy

series ordinal

2

1 reference

24 August 2017

language of work or name

English

0 references

publication date

1 April 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

31

1 reference

24 August 2017

issue

4

1 reference

24 August 2017

page(s)

394-407

1 reference

Determinants of chronic renal allograft rejection in cyclosporine-treated recipients

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.394

Current and evolving immunosuppressive regimens in kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.394

Antihypertensive treatment with calcium channel blockers: pharmacological pornography or useful intervention?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.394

Long-term graft survival with neoral and tacrolimus: a paired kidney analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.394

Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.394

A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.394

Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.394

Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.394

Improved cardiovascular risk profile and renal function in renal transplant patients after randomized conversion from cyclosporine to tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.394

Conversion from cyclosporine to tacrolimus in patients at risk for chronic renal allograft failure: 60-month results of the CRAF Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.394

Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.394

Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.394

Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.394

Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.394

Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.394

Reduced exposure to calcineurin inhibitors in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.394

Immunosuppressive drugs for kidney transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.394

T cell costimulation: a rational target in the therapeutic armamentarium for autoimmune diseases and transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.394

The B7-CD28/CTLA-4 costimulatory pathways in autoimmune disease of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.394

The role of T-cell costimulatory activation pathways in transplant rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.394

CD3/CD28 costimulation-induced NF-kappaB activation is mediated by recruitment of protein kinase C-theta, Bcl10, and IkappaB kinase beta to the immunological synapse through CARMA1

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.394

T-cell regulation by CD28 and CTLA-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.394

B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.394

CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.394

Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.394

Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.394

T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.394

Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.394

Assessment of belatacept-mediated costimulation blockade through evaluation of CD80/86-receptor saturation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.394

A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.394

Costimulation blockade with belatacept in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.394

Costimulation targeting therapies in organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.394

Five-year safety and efficacy of belatacept in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.394

Expanded criteria donors for kidney transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.394

Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.394

Lymphoproliferative disease after renal transplantation in Australia and New Zealand

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.394

Rising incidence of post-transplant lymphoproliferative disease in kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.394

Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.394

Costimulation blockade with belatacept in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.394

Therapeutic monitoring of calcineurin inhibitors for the nephrologist

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.394

Pharmacodynamic monitoring of calcineurin inhibitor therapy: is there a clinical benefit?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.394

Individualization of immunosuppression: concepts and rationale

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.394

Pharmacodynamic monitoring of calcineurin phosphatase activity in transplant patients treated with calcineurin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.394

Therapeutic drug monitoring of immunosuppressive drugs in kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.394

New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.394

An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.394

Pharmacodynamics in the development of new immunosuppressive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.394

Solid organ transplantation: are there predictors for posttransplant noncompliance? A literature overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.394

Comparing renal transplant patients' adherence to free cyclosporine and free tacrolimus immunosuppressant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.394

Belatacept as maintenance immunosuppression for postrenal transplant de novo drug-induced thrombotic microangiopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.394

DETERMINANTS OF GRAFT SURVIVAL AFTER RENAL TRANSPLANTATION1

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.4.394

21 January 2018

Identifiers

DOI

10.1592/PHCO.31.4.394

1 reference

24 August 2017

1 reference